Trial · NCT02964936
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in hemoglobin (Hb) response rate | Baseline and week 24 | Hb response is defined as reaching target values for Hb. |
| Secondary | Change from baseline in the average Hb from Week 18 to Week 24 | Baseline and Weeks 18 to 24 | |
| Secondary | Proportion of participants who achieve the target Hb level at the average of Week 18 to 24 | Weeks 18 to 24 | Hb response defined as average Hb within the target range in this outcome |
| Secondary | Rate of rise in Hb levels (g/dL/week) from week 0 at the earliest date of week 4, time to discontinuation, or time of dose adjustment | Up to Week 4 | |
| Secondary | Proportion of measurement points with the target Hb level | Weeks 18 to 24 | |
| Secondary | Proportion of participants who achieves the target Hb level at each week | Up to Week 24 | |
| Secondary | Proportion of participants who achieves the lower limit of the target Hb level | Up to Week 24 | |
| Secondary | Time to achieve the lower limit of the target Hb level | Up to Week 24 | |
| Secondary | Change from baseline in Hb level to each week | Baseline and Up to Week 24 | |
| Secondary | Quality of life assessed by EQ-5D-5L | Up to Week 24 | EQ-5D: EuroQol 5 Dimension 5 Levels |
| Secondary | Quality of life assessed by FACT-An | Up to Week 24 | FACT-An: Functional Assessment of Cancer Therapy-Anemia |
| Secondary | Number of participants with abnormal Vital signs and/or adverse events related to treatment | Up to Week 24 | |
| Secondary | Safety assessed by body weight | Up to Week 24 | |
| Secondary | Safety assessed by incidence of adverse events | Up to Week 24 | |
| Secondary | Safety assessed by standard 12-lead electrocardiogram | Up to Week 24 | |
| Secondary | Number of participants with abnormal Laboratory values and/or adverse events related to treatment | Up to Week 24 | |
| Secondary | Plasma concentration of unchanged ASP1517 | Up to Week 24 | |
| Secondary | Average hematocrit level | Up to Week 24 | |
| Secondary | Average reticulocyte level | Up to Week 24 | |
| Secondary | Average iron (Fe) level | Up to Week 24 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02964936/registered